For example, recent intervention studies with the innate immune system activator granulocyte-macrophage colony-stimulating factor (GM-CSF; or sargramostim) in animal models of DS, AD, and normal aging have provided preclinical evidence that, during the early stages of AD, activation of the innate immune system may be beneficial [103]. The gene discussed is CSF2; the disease is Dravet syndrome.